68

Highlights in Translational Science: Retina I Symposium im Rahmen der DOG 2023
Do22

Highlights in Translational Science: Retina I Symposium im Rahmen der DOG 2023
Do22

Datum
28.09.2023, 10:15 - 11:30
Symposium
Berlin
Sprache
Englisch
Gebühren ab
gebührenfrei
Veranstalter
DOG - Deutsche Ophthalmologische Gesellschaft e.V.
Organisator

INTERPLAN AG
Congress, Meeting & Event Management AG
Landsberger Straße 155
DE - 80687 München
Tel.: +49 (0)89 548 234 35

This symposium will bring together internationally highly achieved clinicians and scientist to discuss the development of “bench to bedside" approaches in retinal diseases.
  • Basisinformation
    Datum
    28.09.2023, 10:15 - 11:30
    Symposium
    Berlin
    Sprache
    Englisch
    Gebühren ab
    gebührenfrei
    Veranstalter
    DOG - Deutsche Ophthalmologische Gesellschaft e.V.
    Organisator

    INTERPLAN AG
    Congress, Meeting & Event Management AG
    Landsberger Straße 155
    DE - 80687 München
    Tel.: +49 (0)89 548 234 35

  • VERANSTALTUNGSORT
    Estrel Convention Center I Raum VI + VII
    Sonnenallee 225
    12057 Berlin, DE
  • Programm

     

     

     

    The symposium will be opened by Prof. Lois Smith, Harvard Medical School, Boston, who has developed the mouse model of oxygen-induced retinopathy in the 1990s. This model was used to lay the foundations of intravitreal anti-VEGF treatment and has thus had a tremendous impact on our current clinical treatment of wet AMD, DME and many other retinal diseases. Prof. Mike Sapieha, University of Montreal, Canada, will describe his experience in developing new molecules “beyond VEGF” from an academic laboratory into clinical trials to target unmet needs in retinal disease. Maximilian Gerhardt, Ludwigs-Maximilian University Munich, Germany, will take us onto a journey into the world of inherited retinal diseases and gene therapy and describe how novel target molecules are identified and targeted in clinical trials. The symposium will close with a talk by Ann Hellström, University of Gothenburg, Sweden, who will share her experiences from bringing drugs from the laboratory into clinical trials. Prof. Hellström has designed and conducted several investigator-initiated trials (IITs) in multicenter setting to investigate, amongst others, the role of IGF-1 and omega-3 fatty acids in retinopathy of prematurity (ROP). She is currently leading a clinical trial to investigate dexamethasone eye drops in the prevention of severe ROP. Combined, this symposium will offer stimulating presentations for both clinicians and scientists to show how new ideas can emerge from academic laboratories or clinical settings and find their way through the various steps of pre-clinical and clinical validation into the clinic - and in the end change the way we understand and treat a disease.

  • Gebühren
    Fachärzte/-innen
    Gebühren ab
    gebührenfrei
    Ärzte/-innen in Weiterbildung
    Gebühren ab
    gebührenfrei
    Studenten/-innen
    Gebühren ab
    gebührenfrei
    medizinisches Fachpersonal
    Gebühren ab
    gebührenfrei
    Orthoptisten/-innen
    Gebühren ab
    gebührenfrei
    Die Teilnahme am Symposium setzt die Anmeldung zum Kongress voraus. Die Kosten hierfür entnehmen Sie bitte der Hauptveranstaltung (ID: 10957).
  • Buchung / Anmeldung

    Bitte wenden Sie sich direkt an den Organisator.

  • Zertifizierung
    Zertifizierung beantragt für CME Punkte bei der Ärztekammer Berlin
    Es wurden für die Teilnahme am DOG Kongress 2023 CME Punkte bei der Ärztekammer Berlin beantragt.
  • Sponsoren

Veranstaltung teilen